Proactive Investors - Run By Investors For Investors

Roth analyst bullish on Eyenovia stock after reporting 1Q results in range of expectations

A Roth Capital Partners analyst maintains a Buy rating with a $15 price target as two pivotal trials remain on track
The company plans to launch studies of two drugs to treat myopia in children and glaucoma

Eyenovia Inc’s (NASDAQ:EYEN) stock remains a Buy at Roth Capital Partners after first-quarter results released Tuesday were in range with Wall Street’s expectations.

Analyst Scott Henry maintained a Buy rating with a $15 price target based in part on two pivotal trials the ophthalmic biopharmaceutical company is prepared to start in the second half of 2019, as well as the company’s planned submission of a new drug application for MicroStat in 2020.

In its earnings report, Eyenovia said the two studies are on track. The MicroProst Phase 3 program will study the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension. The study is expected to start in the fourth quarter. 

The MicroPine Phase 3 study will be aimed at reducing the progression of myopia in children, and is slated to begin in the third quarter.

“We kicked off 2019 with a number of successes that further validate our novel approach in ophthalmology that we believe will help us advance multiple programs towards Phase 3 initiations this year,” said Eyenovia CEO Sean Ianchulev in a statement.

READ: Eyenovia pushes ahead with eye drug trials as it unveils 4Q results

Eyenovia, based in New York City, reported that it ended the quarter with about $14.3 million in cash and cash equivalents. The company also recorded a net loss of about $5.9 million, or $0.50 per share, compared to a loss $3.4 million, or $0.45 per share, in the first quarter of 2018.

Henry wrote that the net loss was slightly off his $0.49 target, and  “fundamentally, we found the quarter as expected.”

Shares recently traded up 2.5% to $5.12 a piece.

Roth makes a market in shares of Eyenovia, and as such, buys and sells from customers on a principal basis.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full EYEN profile View Profile

Eyenovia Inc Timeline

Related Articles

February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use